Recruiting

NCT Number: NCT07335627

Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection

Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained.

The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections.

The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Streptococcus Infection Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Streptococcal Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Aurélie BALDOLI, MD

PRINCIPAL_INVESTIGATOR

Clément THEIS, MD

PRINCIPAL_INVESTIGATOR

Cécile ROND-OUSTAU, MD

SUB_INVESTIGATOR

Julien GODET, Statistician

SUB_INVESTIGATOR

Kevin BOUILLER, MD

PRINCIPAL_INVESTIGATOR

Martin MARTINOT, MD

PRINCIPAL_INVESTIGATOR

Stéphane KLEIN, MD

CONTACT

[email protected]

33 3 68 76 52 32

Stéphane KLEIN, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (aged 18 years or older) at the time of surgery for infection
Probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria
Patient operated on in one of the associated centers between 2013 and 2024

Exclusion criteria

Patient who underwent joint resection or amputation
Patient who was treated with suppressive antibiotic therapy (defined as antibiotic treatment lasting more than 6 months) which was decided upon prior to surgery

Treatment and study plan

Primary outcomes

Therapeutic success of the medical-surgical strategy

Time frame: One year after the end of antibiotic treatment

Therapeutic success of the medical-surgical strategy defined as: patient showing no clinical signs of infection, no need for repeat surgery one year after the end of antibiotic treatment, and no repeat antibiotic treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Stéphane KLEIN, MD

CONTACT

[email protected]

33 3 68 76 52 32

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: CASPR

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jan 13, 2026
Registry last updated: Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed